There's plenty of tech advancements as well, with the Global AI in Oncology Market growing at a rapid 35% CAGR, towards US$13.6 billion by 2032. Analysts at Spherical Insights project the global ...

The breast cancer drug Enhertu will be added to China’s national health insurance scheme beginning in the new year — despite ...

We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a ...

But in July 2024 she learned the treatment had come with a rare side effect, therapy-related acute myeloid leukaemia, an ...

The latest health news includes China allowing foreign-owned hospitals in major cities, and the inclusion of AstraZeneca's ...

Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use ...

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...